key: cord-1053073-b4sc9pah authors: Heida, Rick; Bhide, Yoshita C.; Gasbarri, Matteo; Kocabiyik, Özgün; Stellacci, Francesco; Huckriede, Anke L.W.; Hinrichs, Wouter L.J.; Frijlink, Henderik W. title: Advances in the development of entry inhibitors for sialic-acid-targeting viruses date: 2020-10-21 journal: Drug Discov Today DOI: 10.1016/j.drudis.2020.10.009 sha: 5e768c99470ff6579f9a395db4b5330abc5bdcb4 doc_id: 1053073 cord_uid: b4sc9pah Over the past decades, several antiviral drugs have been developed to treat a range of infections. Yet the number of treatable viral infections is still limited, and resistance to current drug regimens is an ever-growing problem. Therefore, additional strategies are needed to provide a rapid cure for infected individuals. An interesting target for antiviral drugs is the process of viral attachment and entry into the cell. Although most viruses use distinct host receptors for attachment to the target cell, some viruses share receptors, of which sialic acids are a common example. This review aims to give an update on entry inhibitors for a range of sialic-acid-targeting viruses and provides insight into the prospects for those with broad-spectrum potential. Antiviral drugs are highly valuable for slowing down or clearing established viral infections. In addition, most of these drugs can be given prophylactically, which is beneficial for high-risk groups. However, the actual number of treatable viral infections is limited. Of the 219 viruses currently known to be infectious to humans [1] , only nine are treatable with antiviral drugs [2] . For this reason, there is an urgent need to investigate further antiviral strategies. Antiviral drugs can interfere with any step of the viral life cycle. An interesting target for antiviral therapy is the process of viral attachment and entry. However, entry inhibitors have seen limited clinical application, with only seven compounds being approved by the US Food and Drug Administration (FDA) for four virus types: human immunodeficiency virus, varicella zoster virus, herpes simplex virus and respiratory syncytial virus [2] . Moreover, these drugs are not commonly prescribed owing to their expense and the availability of more cost-effective alternatives. Therefore, novel ways of targeting viral entry processes should be urgently explored. Viruses deploy several mechanisms for entry into the host cell, using distinct moieties on the cell membrane as a receptor. Such moieties include sialic acids, which are In addition to their role in normal physiology, sialic acids are involved in the interaction of many pathogens with their host cells. Along with parasites and bacteria, a large number of viruses have been shown to interact with sialic acids for cellular attachment and entry [3] . However, the specific sialic acid derivative that serves as the attachment receptor differs according to the virus strain and depends on the receptor binding site of the viral attachment protein. For this reason, viral tropism is mostly dependent on the location of the attachment receptor. Interestingly, several viruses have been described to be not strictly dependent on sialic acids for J o u r n a l P r e -p r o o f attachment and entry, but rather use sialic acids as a co-receptor or enhancer of attachment. At least 16 viral genera have been identified to interact with sialic acids in some way for their entry process, as reviewed elsewhere [11] . Because of the profound role of sialic acids in the viral entry process, an entry inhibitor that prevents virus attachment to sialic acids would have the potential to serve as a broad-spectrum antiviral drug and might therefore be of high therapeutic relevance. This review provides an overview of the epidemiology of a selection of viruses that use sialic acids as their main cellular receptor to initiate entry, and we discuss the current development status of entry inhibitors targeting these viruses. Both sialic-acid-mimicking and sialic-acid-targeting drugs are discussed to highlight the most promising entry inhibitors, which are those with broad-spectrum activity. The following sections provide an overview of the most clinically relevant sialic-acidtargeting viruses for which effective antiviral therapy is urgently needed. We discuss current modes of treatment for these viruses and highlight advances in the development of entry inhibitors, if applicable. The chemical structures of the entry inhibitors described in this review are depicted in Table 1 . Although these drugs have been effective in treating the disease, the emergence of resistance against the currently used antivirals is a major concern for effective treatment and prophylaxis of influenza in the future [34] [35] [36] [37] . Therefore, the development of novel drugs or combination therapies that target multiple pathways of the viral replication cycle remains necessary [38] . In this light, entry inhibitors might be a promising alternative. Entry inhibitors for influenza can be generally divided into two categories on the basis of their mechanism of action. The first category includes compounds that interfere with the initial attachment process of the virus. This can be done by directly targeting host sialic acids or by targeting the receptor-binding domain of the virus, using sialic acid analogues as a decoy receptor. Both of these mechanisms disable the ability of influenza-virus particles to bind sialic-acid molecules on the host cell. The other category includes compounds that bind to the haemagglutinin stalk, affecting the fusion of the viral envelope with the endosomal membrane. Although fusion inhibitors do not block the initial attachment, they do block the release of the viral genome into the cytoplasm and thereby interfere with the last step of the viral entry process. In the past five years, a plethora of novel influenza entry inhibitors have shown potency in vitro [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . An overview of compounds that have been further evaluated in the preclinical or clinical phase is given in Table 1 . Interestingly, only a few of the highlighted entry inhibitors interfere with the initial attachment process of the influenza virus (i.e., with the receptor-binding site of haemagglutinin or with sialic acids). The primary reason for this is that compounds that target the receptor-binding J o u r n a l P r e -p r o o f site need to bind the haemagglutinin protein in such a way that they do not lose efficacy on seasonal mutation of the virus, as is the case with neutralizing antibodies from the host. In this context, it should be remarked that haemagglutinin is found in a trimeric form [59] . This implies that it ideally binds to three sialic-acid moieties on the cell surface. Such a concept (i.e., multiple ligands binding to multiple targets) is known as multivalency and is highly important in several biological and pathogenic interactions (Box 1). The concept of multivalency is widely used in the development of potentially broad-spectrum sialic-acid-based receptor analogues, which are described in further detail later in this review. Apart from using multivalent drugs to block the receptorbinding site, another strategy is to use monoclonal antibodies that bind to more conserved parts of the HA1 head domain [60] . However, none of the abovementioned compounds has been evaluated in clinical trials. Besides targeting haemagglutinin to block the attachment process, another way is to directly target host sialic acids. Arguably the most promising influenza entry inhibitor using this method is DAS-181, which is a recombinant fusion protein that can enzymatically cleave terminal sialic acids from carbohydrate chains on the host-cell membrane [61, 62] . Because DAS-181 has shown promising results as a broadspectrum drug, we discuss it later on in this review. Another study focused on using multivalent proteins derived from the binding domains of bacterial sialidases to target host sialic acids. However, the compounds, which mask the receptor rather than cleaving it, only worked prophylactically, indicating that the virus successfully competed for sialic-acid binding when the same dose was administered therapeutically [63] . Most of the compounds that have been evaluated in preclinical or clinical settings target the stalk domain, the part of the haemagglutinin protein that is involved in the fusion process and is generally more conserved [64] . One interesting example is umifenovir (trade name: Arbidol), a drug that has been licensed in Russia and China and is claimed to have activity against a broad variety of influenza strains [65] [66] [67] [68] . The proposed working mechanism is that by interacting with the upper region of the stalk, the drug prevents the low-pH-induced protein rearrangements that are necessary to elicit fusion of the virus with the cell membrane [69] . Other clinically relevant compounds that target the stalk include monoclonal antibodies [70] [71] [72] . Of these, five are currently in clinical evaluation (Table 2) . The Paramyxoviridae family consists of enveloped negative-sense, single-stranded in vitro [102] . Based on this, an even more potent trivalent compound was designed, which was highly effective in cell-attachment and -infection assays [103] . In addition to binding CAR, the gastroenteritis-causing AdV-G52 was recently found to bind α-2,8-linked polysialic acids, which are a unique type of post-translationally modified sialic acid that is usually found in brain tissue [104] . Also, AdV-D26 has recently been shown to rely on sialic acids for cell entry [105] . Future insights into the binding mechanisms of these viruses might pave the way for new types of potentially broadspectrum entry inhibitors for sialic-acid-dependent AdV subtypes. Polyomaviruses include a variety of non-enveloped double-stranded DNA viruses [106] . Their icosahedral-shaped capsid consists of three proteins, namely VP1, which is the viral attachment protein and makes up most of the viral capsid [107] , VP2 and VP3, which are probably involved in insertion of the viral genome into the host cell nucleus [108] . Around 14 different human polyomaviruses have been identified [109] . The two strains that are most infectious to humans are BK virus (BKV) and JC virus (JCV), both of which can be further divided into different subtypes [107] . The newly discovered Merkel cell polyomavirus was recently added to this list [110] . [107] . Mostly, the virus latently resides in the kidneys and peripheral blood, making the infection asymptomatic or mildly symptomatic for the majority of infected individuals [111] . However, in immune-deficient individuals, the virus might start to replicate again and cause specific disease. In this context, BKV is a common cause of nephropathy, mostly occurring in people who have undergone a kidney transplant [112, 113] . By contrast, recurring infections with JCV can lead to progressive multifocal leukoencephalopathy. It is thought that JCV infiltrates the brain tissue via B cells in the blood, from where it can cause a lytic infection in myelinproducing oligodendrocytes and in astrocytes [114, 115] . In humans, Merkel cell polyomavirus has been found to be the primary cause of Merkel cell carcinoma, which is a highly aggressive form of skin cancer [110, 116] . Different types of human polyomavirus interact with different sialic-acid residues on host cells. JCV has been found to interact with α-2,6-linked sialic acids [117, 118] , as well as with α-2,3-linked sialic acids [119] . BKV was found to interact with α-2,3linked sialic acids only [120] . Merkel cell polyomavirus has also been found to rely on α-2,3-linked sialic acids for attachment, although it can use α-2,6-linked sialic acids as well [121, 122] . With knowledge of the receptors used for attachment, it might be possible to design antiviral drugs based on the viral entry mechanism. Using computational screening, Yatawara et al. identified four different compounds that blocked JCV infectivity in an in vitro setting involving the astrocyte cell line SVGA. Of those, the small-molecule inhibitor AY4 was the most effective inhibitor of infection, albeit with low affinity. AY4 was shown to directly bind to the VP1 attachment protein to block J o u r n a l P r e -p r o o f viral attachment [123] . Because the options for treating polyomavirus infections and related diseases are limited, the development of novel antiviral compounds is important. Coronaviruses (CoVs) belong to the Coronaviridae family and are enveloped, positive-sense, single-stranded RNA viruses. The abundant spike (S) glycoprotein functions as the viral attachment protein. The S protein is composed of two subunits, S1 and S2: S1 contains the receptor-binding site, whereas S2 contains the fusion machinery [124] . CoVs are divided into four subtypes (α, β, γ and δ). Of these, only certain α-CoVs (CoV-229E and CoV-NL63) and β-CoV (OC43-CoV, HKU1-CoV, SARS-CoV, MERS-CoV and the recently emerged SARS-CoV-2) infect humans, and are all thought to be of zoonotic origin [124] [125] [126] . CoVs have emerged unexpectedly three times over the past two decades, with the most recent example being the SARS-CoV-2 pandemic, which causes respiratory disease designated as COVID-19 [126] . Overall, most CoVs cause mild respiratory disease varying from cough to fever. However, symptoms can be worse, especially in susceptible groups such as elderly people and individuals with an underlying illness. To manage the current pandemic and prevent future epidemics or pandemics, the development of novel antiviral compounds has become urgent. Many clinical trials of potential antiviral compounds such as nucleoside analogues and corticosteroids have failed [127] ; thus, other strategies for treating patients are needed to prevent future outbreaks. In that respect, entry inhibitors that target the viral receptor or receptor-binding site of the CoV S protein might be of therapeutic value. Several of the β-CoVs have been shown to interact with sialic acid moieties for J o u r n a l P r e -p r o o f cell entry processes. Both OC43-CoV and HKU1-CoV specifically target 9-Oacetylated sialic acids [124, 128, 129] , which are modified sialic acids that are thought to have an important role in many biological and pathological processes [130, 131] . Attachment occurs via the receptor-binding site in the S1 domain of the S protein [124, 132, 133] . Recently, the small molecule EK1, derived from the HR2 domain of the OC43-CoV spike protein, was found to elicit high fusion-inhibitory activity against various human CoVs, underlining the potential for its development as a broadspectrum drug [134] . MERS-CoV interacts with dipeptidyl peptidase 4 as its receptor to enter the cell [135, 136] , using α-2,3-linked sialic acids as a co-receptor for attachment [137, 138] . Although monoclonal antibodies that target the sialic-acidbinding S1a domain might provide a synergistic effect in combination treatment regimens, sialic acids do not seem to be essential for MERS-CoV infectiveness [139] . Enterovirus D68 (EV-D68) is a member of the Picornaviridae family, which is a large family consisting of non-enveloped, single-stranded RNA viruses [140] . Unlike most other enteroviruses, EV-D68 infects the upper respiratory tract, primarily causing disease in the paediatric population [141] . In most patients, the virus causes symptoms similar to those of the common cold. However, in some cases, infections are accompanied by acute flaccid myelitis (AFM), a polio-like disorder that is characterized by lesions in the spinal cord, which can eventually cause paralysis [142, 143] . Most of these patients suffer from underlying respiratory disease, have a history of organ transplantation or are immunocompromised in another way [144] . However, whether there is a causal relationship between the virus and AFM pathogenesis is still a matter of debate [141, 145, 146] . The emergence of more J o u r n a l P r e -p r o o f severe cases, together with recent outbreaks, have led to an increased interest in the virus and in disease pathogenicity. In recent years, EV-D68 has been found to exploit sialic acids for attachment and for cell entry [147] . It was found that these sialic acid molecules are terminally linked via α-2,6-linkers [148] to intercellular adhesion molecule 5 (ICAM5), which is found in the upper respiratory tract as well as on neurons [149] , with the latter providing a possible link to the pathogenesis of AFM. Interestingly, it was found that EV-D68 can also exploit α-2,3-linked sialic acid in the lower respiratory tract for infection, increasing the probability of the virus successfully infecting its host [150] . Owing to this, interest in the development of entry inhibitors for the currently untreatable infection has increased. Rhoden et al. were among the first to test existing antivirals for the treatment of EV-D68 in a cell-based assay, one of which was DAS-181. They found that the drug was able to reduce the viral cytopathic effect on infection with three EV-D68 strains isolated from the 2014 outbreak, and one prototype strain [151] . However, it is unclear whether these results can be translated to an in vivo system, partly owing to the lack of suitable animal models. The Zika virus (ZIKV) is a single-stranded, enveloped RNA virus in the Flaviviridae family. It is transmitted via mosquitoes, but once it has infected a host, it can be transmitted through the congenital and perinatal route, and it can be sexually transmitted [152] . Infection with ZIKV can affect all age groups and is usually asymptomatic or mildly symptomatic, generally resolving within 2 weeks. However, several reports have indicated that ZIKV infection of pregnant women can cause congenital brain abnormalities of the foetus such as microcephaly, in which the foetus J o u r n a l P r e -p r o o f has an abnormally small brain, leading to severe cognitive and motor deficits [153, 154] . Although the virus has caused infections only sporadically in the past, several outbreaks have emerged since 2007, which shows the need for preventive measures [152] . People are usually advised to use mosquito nets or DEETcontaining insect repellents to prevent initial transmission, but pregnant women who have become infected might benefit from antiviral therapy. ZIKV has been shown to infect a range of cells from the reproductive tract, as well as certain brain cell types, including neuronal cells from the foetal brain [155] . The primary surface protein of ZIKV is the envelope (E) protein. It is thought that the E protein interacts with several cellular attachment factors before cell entry, with each individual interaction contributing to its binding avidity to the host cell [156] . Once the binding strength has reached the threshold, the virus is internalized via clathrinmediated endocytosis. ZIKV was recently found to use α-2,3-sialic acids for cell entry, supposedly as a factor contributing to ZIKV internalization after attachment has taken place [157] . In a study conducted by Fink et al., it was found that the anti-influenza drug umifenovir caused inhibition of ZIKV infection in a range of cell types, including vaginal and cervical epithelial cells. Although the authors propose that the drug inhibits viral entry, the exact mechanisms of inhibition are unknown [158] . Additional insights into the entry mechanism and specific attachment factors of ZIKV might lead to specific therapy for pregnant women at risk of infection. Although most studies on antiviral therapies focus on virus-specific pathways, it might be more promising to search for drugs that affect mechanisms common to multiple J o u r n a l P r e -p r o o f viruses: for example, the mechanism of viral entry into the host cell. To develop such broad-spectrum entry inhibitors in the context of sialic acid-targeting viruses, they should either target the sialic-acid residues or mimic them by making use of drugs that function as decoy receptors to block the virus from binding to the host cell. Below, both strategies are discussed. One of the potentially broad-spectrum antiviral drugs that target the entry pathway is DAS-181, a recombinant neuraminidase analogue that cleaves sialic-acid residues from carbohydrate chains on host epithelia. In this way, virus binding to the host cell can be indirectly inhibited. More specifically, DAS-181 is a fusion protein that contains both the catalytic domain of the sialidase enzyme of Actinomyces viscosus and the anchoring domain of human amphiregulin [61] . Because the drug is administered via inhalation, it prevents entry of the virus directly at the airway epithelium, which is thought to keep adverse systemic side effects to a minimum [159] . DAS-181 is considered to be a promising candidate for the treatment of infections with sialic-acid-targeting viruses that are transmitted via the respiratory tract because it targets the host receptor rather than the virus, and thereby circumvents any losses of efficacy related to viral mutations. In addition, DAS-181 has shown to be effective for HPIV infections. In preclinical studies, administration of the drug has been shown to lead to a significant reduction in the number of HPIV-infected cells in vitro and in vivo [161] . Furthermore, the drug has successfully passed a phase II clinical trial in which its efficacy was investigated in immunocompromised patients with parainfluenza infection (NCT01644877) [162] . Aside from the promising advances regarding its use for the treatment of influenza and parainfluenza infections, DAS-181 has shown high therapeutic efficacy against EV-D68 at concentrations in the nanomolar range [151] . However, concerns have been raised owing to the finding that isolated strains of EV-D68 might evade the drug because they are capable of infecting desialylated cells, although it is not known whether these strains actively circulate in the human population [150] . The cleavage of viral attachment receptors seems like a promising strategy, but it is uncertain whether the removal of sialic-acid residues from the respiratory epithelium leads to adverse side effects. Concerns over the use of neuraminidase J o u r n a l P r e -p r o o f analogues are primarily based on the hypothesis that neuraminidase treatment makes the patient more prone to secondary infections by bacteria such as Streptococcus pneumoniae [164] [165] [166] . This possibility was strengthened after treatment with the neuraminidase inhibitor oseltamivir in influenza-infected mice was reported to lead to a decrease in cases of secondary bacterial pneumonia [165] . Additional concerns were raised over the possibility that cleavage of sialic-acid residues by neuraminidase might expose cryptic receptors that are necessary for the opportunistic bacteria to adhere [167, 168] . This hypothesis has been tested in in vivo colonization studies with S. pneumoniae in influenza-infected mice, which showed that DAS-181 had no effect on bacterial growth or might even reduce the risk of acquiring a secondary bacterial infection [169] . However, because sialic acids are necessary for several physiological processes, the long-term effects of their removal should be considered carefully. Moreover, another limitation might be that the removal of sialic acids by sialidases could lead to the emergence of highly resistant escape mutants that do not strictly depend on the sialic-acid interaction. Notwithstanding these concerns, DAS-181 is currently the only compound in advanced clinical development that tackles sialic-acid-targeting viruses by targeting the cellular receptor itself. Another strategy for broad-spectrum targeting is to mimic the cellular receptor. This can be done by using compounds that function as a decoy, thereby competing with the cellular receptor to bind the virus (i.e., competitive-binding inhibitors). A number Early studies of the use of sialic-acid-containing compounds to inhibit viral infection primarily investigated naturally occurring soluble substances that contain sialic-acid molecules, such as egg white, serum and respiratory mucus [170] . These substances were shown to be able to compete with cell-associated sialic acids for the binding of influenza virus. It should be noted that the inhibitory capacity of these molecules was found to be highly dependent on several parameters such as size, rigidity and accessibility to haemagglutinin, as well as on the susceptibility of the substance to being neutralized by neuraminidase molecules [170] . Other interesting examples of molecules that are thought to contribute to the defence mechanism of the host are mucins [171, 172] and surfactant proteins [173] [174] [175] [176] , which are produced by cells of the respiratory tract as a component of mucus and contain a wide variety of carbohydrates, including sialic acid. These compounds, which are part of the innate immune system, can function as naturally occurring decoy receptors against intruding sialic-acid-targeting pathogens, leading to aggregation of the virus particles and an enhanced ability of phagocytic cells to recognize such particles, as has been shown recently [176] . As well as naturally occurring molecules, several synthetic sialic-acid analogues have been tested against influenza, albeit with limited success. The efficacy of these drugs increased markedly with the development of the first multivalent inhibitors, although this success varied for different strains of influenza [170] . To overcome the problem of strain-dependent efficacy of the inhibitors, research focused on moieties that are essential to most influenza strains, such as 6′-SLN (Figure 3) . Synthetic compounds containing 6′-SLN epitopes were shown to J o u r n a l P r e -p r o o f effectively inhibit influenza A virus infection in mice, both prophylactically and therapeutically [177, 178] . In a series of studies conducted by Papp et al., sialic-acidfunctionalized nanoparticles were shown to effectively inhibit influenza virus infection in vitro by binding to viral haemagglutinin in a multivalent manner [179, 180] . Another application of multivalent receptor analogues was introduced by Wang and colleagues, who functionalized liposomes with sialylneolacto-N-tetraose c (LSTc) glycans. The compounds, which acted like polymeric receptor decoys, were able to inhibit infection with several influenza strains, both in vitro and in vivo [181] . To optimize drugs that target the receptor-binding site of influenza, Kwon and colleagues designed multivalent 6′-sialyllactose-polyamidoamine (6′SL-PAMAM) conjugates with well-defined linker spacings to match the spacing of HA molecules on the viral envelope, and were therefore able to inhibit infection of mice with a lethal dose of H1N1 [182] . On the basis of this, Günther et al. recently fine-tuned the design of these conjugates to bear more functional groups, and were able to confirm the efficacy of the compounds against various human and avian influenza strains [41] . Other interesting compounds that target the receptor-binding site are linear polyglycerol sialosides. By optimizing the ligand densities, these compounds were shown to prevent influenza infection in mice in a superior fashion compared with dendritic polyglycerol sialosides. The authors state that the efficacy of dendritic polyglycerol sialosides was probably affected by steric shielding [183] . Another interesting application of multivalent receptor decoys for the treatment of influenza was introduced recently by Lauster and colleagues, who used bacteriophage capsids functionalized with sialic-acid moieties as a decoy for the virus. With ligand arrangements matching the distance of the receptor-binding sites of trimeric influenza J o u r n a l P r e -p r o o f haemagglutinin, the systems were able to multivalently bind to influenza virions, thereby efficiently blocking viral attachment in vitro, ex vivo and in vivo [184] . Although the concept of sialic-acid-receptor analogues is promising, not many studies have been conducted on this idea in recent years. This lack of interest could be partially attributed to the poor translatability of in vitro results to the clinical setting. The low in vivo effectiveness of sialic-acid-receptor analogues is intrinsic to their mechanism of action; such compounds are competitive binding inhibitors that interact with the virus, thus preventing the infection just above a certain concentration. On dilution, a usual condition in the in vivo setting, the reversible interaction is lost, and the drug releases an intact virion that can restart an infection cycle, which explains the lack of efficacy in vivo. As such, the drug has a so-called virustatic effect. Arguably, a superior approach would be based on a virucidal mechanism of action. A virucidal drug is able to irreversibly inhibit a virus, so that the inhibition is retained even on dilution (Figure 4) . Compounds that are based on a virucidal mechanism of action enhance the properties of a standard competitive inhibitor because they permanently inactivate the virus. Examples of virucidal compounds are bleach, disinfectants and strong acids, which are all used to deactivate viruses in vitro but are also extremely toxic. Therefore, they are not suitable as drug candidates. One way of designing non-toxic virucidal drugs is to couple decoy receptors to nanoparticles via long, flexible and hydrophobic linkers. The validity of this concept has been shown for heparan sulfate proteoglycans (HSPGs), which are common receptors for many viruses. The modified compounds were shown to bind to several HSPG-targeting viruses in a multivalent manner, leading to irreversible viral deformation, probably owing to a local increase in pressure [185] . Recently, this approach has been successfully translated to sialic-acid-targeting viruses using natural molecules as a core. Specifically, -cyclodextrins were modified with long and hydrophobic linkers, bearing either 6′-SLN or 3′-SLN as functional group. These compounds were able to irreversibly inhibit different strains of human and avian influenza in the nanomolar range. The results were confirmed ex vivo and validated in vivo [186] . Taken together, sialic-acid-based receptor analogues might hold promise as entry inhibitors for sialic-acid-dependent viruses, especially for influenza. The possibility of using monosaccharides (such as Neu5Ac) could pave the way for broad-spectrum antiviral drugs with a virucidal mechanism of action. Because the number of approved antiviral drugs is limited and new virus strains continue to emerge, the urgency of developing novel therapeutic strategies remains high. Despite numerous attempts to find efficient antiviral drugs, in the end, many of them will fail in phase II or III studies: a frequent occurrence in drug development. Therefore, more effort should be put into the development of potent, preferably broad-spectrum antivirals. In addition, the administration route should be considered. For example, respiratoryvirus infections are likely to be treated most optimally with antivirals that are administered via the respiratory tract. Because several viruses share a common attachment receptor, we think that focusing on the mechanism of viral entry could open doors to the development of compounds with broad-spectrum activity. Many viruses use sialic-acid residues as their receptor, so this review has focused on the process of viral entry of these sialic-acid-targeting viruses and the current status of J o u r n a l P r e -p r o o f entry-inhibitor development, including those which might have broad-spectrum activity. Although numerous studies have been conducted on entry inhibitors targeting this group of viruses, most of the compounds studied have strain-specific targets. Therefore, we think that receptor-targeting compounds that directly interfere with the attachment of the virus to sialic acids, as well as multivalent sialic acid receptor analogues, deserve more attention, because they might have the potential to broadly combat a wide variety of sialic-acid-targeting viruses. To the best of our knowledge, the concept of multivalency has been observed with all viral attachment proteins that have been structurally resolved to date. Multivalency is in fact common in biological systems [187] . It is understood that nature uses it to increase binding strength and consequently selectivity [188, 189] . On the basis of this, many receptor analogues have been designed to be multivalent: that is, they were designed as macromolecules containing many repetitive units of the viral receptor to better bind to the virus (Figure 3 ). Another advantage of multivalent drugs over monovalent compounds is that a lower dose can be used to elicit the required effect [188] . The design of these compounds further requires the fine-tuning of several parameters such as scaffold geometry and the flexibility of the linkers, their length and their relative distance [182, 188, 190] . J o u r n a l P r e -p r o o f Human viruses: discovery and emergence Isolation and characterization of human monoclonal antibodies that recognize the influenza A(H1N1)pdm09 virus hemagglutinin receptor-binding site and rarely yield escape mutant viruses Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein Prevention of influenza by targeting host receptors using engineered proteins Universal influenza virus vaccines that target the conserved hemagglutinin stalk and conserved sites in the head domain Characteristics of arbidol-resistant mutants of influenza virus: Implications for the mechanism of anti-influenza action of arbidol Sensitivity of various influenza virus strains to arbidol. Influence of arbidol combination with different antiviral drugs on reproduction of influenza virus A Umifenovir susceptibility monitoring and characterization of influenza viruses isolated during ARBITR clinical study Efficacy and safety of arbidol in treatment of naturally acquired influenza Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol Evaluation of MEDI8852, an anti-influenza a monoclonal antibody, in treating acute uncomplicated influenza Pharmacokinetics of MHAA4549A, an anti-influenza a monoclonal antibody, in healthy subjects challenged with influenza A virus in a phase IIa randomized trial A potent trivalent sialic acid inhibitor of adenovirus type 37 infection of human corneal cells Triazole linker-based trivalent sialic acid inhibitors of adenovirus type 37 infection of human corneal epithelial cells Polysialic acid is a cellular receptor for human adenovirus 52 Human adenovirus type 26 uses sialic acid-bearing glycans as a primary cell entry receptor BK and JC virus: a review Human polyoma viruses and disease with emphasis on clinical BK and JC Role of a nuclear localization signal on the minor capsid Proteins VP2 and VP3 in BKPyV nuclear entry Human polyomaviruses and cancer: an overview Clonal Integration of a polyomavirus in human Merkel cell carcinoma The human polyomaviruses Polyomavirus infection of renal allograft recipients: from latent infection to manifest disease Polyomavirus BK versus JC replication and nephropathy in renal transplant recipients: a prospective evaluation Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy Infectious entry of Merkel cell polyomavirus Infection of glial cells by the human polyomavirus JC is mediated by an N-linked glycoprotein containing terminal alpha(2-6)-linked sialic acids Direct correlation between sialic acid binding and infection of cells by two human polyomaviruses (JC virus and BK virus) An N-linked glycoprotein with α(2,3)-linked sialic acid is a receptor for BK virus Structures of Merkel cell polyomavirus VP1 complexes define a sialic acid binding site required for infection Discrimination between sialic acid-containing receptors and pseudoreceptors regulates polyomavirus spread in the mouse Small-molecule inhibitors of JC polyomavirus infection Structural basis for human coronavirus attachment to sialic acid receptors Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding A novel coronavirus from patients with pneumonia in China Coronaviruses -drug discovery and therapeutic options Human coronavirus HKU1 spike protein uses O-acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein Structures of MERS-CoV spike glycoprotein in complex with sialoside attachment receptors Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein Picornaviridae-the ever-growing virus family Enterovirus D68 -the new polio? Acute flaccid myelitis in the United States Upsurge of enterovirus D68, the Netherlands Global emergence of enterovirus D68: a systematic review Enterovirus D68 and acute flaccid myelitis-evaluating the evidence for causality Contemporary circulating enterovirus D68 strains have acquired the capacity for viral entry and replication in human neuronal cells ICAM-5/telencephalin is a functional entry receptor for enterovirus D68 Enterovirus D68 receptor requirements unveiled by haploid genetics vitro efficacy of antiviral compounds against enterovirus D68 A literature review of Zika virus Zika virus associated with microcephaly Possible association between Zika virus infection and microcephaly -Brazil Zika virus structure, maturation, and receptors Biology of Zika virus infection in human skin cells Cell surface α2,3-linked sialic acid facilitates Zika virus internalization The antiviral drug arbidol inhibits Zika virus Phase 1 clinical trials of DAS181, an inhaled sialidase, in healthy adults A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection A recombinant sialidase fusion protein effectively inhibits human parainfluenza viral infection in vitro and in vivo A randomized, double-blind, placebo-controlled multicenter phase 2 trial to examine the effects of DAS181 in immunocompromised (IC) patients with parainfluenza virus (PIV) lower respiratory tract infection (LRTI) hematopoietic stem cell transplant recipients at a single center Influenza virus neuraminidase contributes to secondary bacterial pneumonia Effect of antiviral treatment on the outcome of secondary bacterial pneumonia after influenza Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza Comment on: Concerns of using sialidase fusion protein as an experimental drug to combat seasonal and pandemic influenza Influenza virus infection: don't forget the role of the mucociliary system! Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection Natural and synthetic sialic acid-containing inhibitors of influenza virus receptor binding Airway mucins and their role in defence against microorganisms Interactions between human respiratory mucins and pathogens Interactions of surfactant protein A with influenza A viruses: binding and neutralization Mechanisms of anti-influenza activity of surfactant proteins A and D: comparison with serum collectins Absence of SP-A modulates innate and adaptive defense responses 177 Polymeric inhibitor of influenza virus attachment protects mice from experimental influenza infection Polymer-bound 6′ sialyl-N-acetyllactosamine protects mice infected by influenza virus Inhibition of influenza virus infection by multivalent sialic-acidfunctionalized gold nanoparticles Inhibition of influenza virus activity by multivalent glycoarchitectures with matched sizes Sialylneolacto-N-tetraose c (LSTc)-bearing liposomal decoys capture influenza a virus Nanostructured glycan architecture is important in the inhibition of influenza A virus infection Linear polysialoside outperforms dendritic analogs for inhibition of influenza virus infection in vitro and in vivo Phage capsid nanoparticles with defined ligand arrangement block influenza virus entry Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism Non-toxic virucidal macromolecules show high efficacy against influenza virus ex vivo and in vivo Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors Multivalency as a chemical organization and action principle Mobility-based quantification of multivalent virus-receptor interactions: new insights into influenza A virus binding mode Influence of length and flexibility of spacers on the binding affinity of divalent ligands Arbidol (umifenovir): a broad-spectrum antiviral drug that inhibits medically important arthropod-borne flaviviruses An investigational antiviral drug, DAS181, effectively inhibits replication of zoonotic influenza a virus subtype H7N9 and protects mice from lethality Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein Pre-and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets Arbidol: A Broad-Spectrum Antiviral Compound that Blocks Viral Fusion Structure and function analysis of an antibody recognizing all influenza A subtypes The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses An in vivo human-plasmablast enrichment technique allows rapid identification of therapeutic influenza A antibodies Phase 2 randomized trial of the safety and efficacy of MHAA4549A, a broadly neutralizing monoclonal antibody Safety and upper respiratory pharmacokinetics of the hemagglutinin stalk-binding antibody VIS410 support treatment and prophylaxis based on population modeling of seasonal influenza A outbreaks The hemagglutinin stem-binding monoclonal antibody VIS410 controls influenza virus-induced acute respiratory distress syndrome Novel small molecule targeting the hemagglutinin stalk of influenza viruses A small-molecule fusion inhibitor of influenza virus is orally active in mice The antihistamine drugs carbinoxamine maleate and chlorpheniramine maleate exhibit potent antiviral activity against a broad spectrum of influenza viruses A sialylated voltage-dependent Ca 2+ channel binds hemagglutinin and mediates influenza A virus entry into mammalian cells Potent influenza A virus entry inhibitors targeting a conserved region of hemagglutinin An amphibian host defense peptide is virucidal for human H1 Adenovirus-D37 [103] IC50 (HCE cell-binding assay This work was supported by the Swiss National Science Foundation (via a Sinergia grant CRSII5_180323 to F.S. and H.W.F.).